Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.2 USD | -0.25% | -6.15% | +41.86% |
Valuation
Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|
Capitalization 1 | 353.5 | 605.7 | - | - |
Enterprise Value (EV) 1 | 353.5 | 500.2 | 468.6 | 468.7 |
P/E ratio | -4.32 x | -4.07 x | -3.81 x | -3.6 x |
Yield | - | - | - | - |
Capitalization / Revenue | - | - | - | - |
EV / Revenue | - | - | - | - |
EV / EBITDA | -4.18 x | -3.38 x | -2.51 x | -2.12 x |
EV / FCF | - | - | - | - |
FCF Yield | - | - | - | - |
Price to Book | - | - | - | - |
Nbr of stocks (in thousands) | 41,105 | 49,649 | - | - |
Reference price 2 | 8.600 | 12.20 | 12.20 | 12.20 |
Announcement Date | 21/03/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - |
EBITDA 1 | - | -31.48 | -84.66 | -147.8 | -186.5 | -221.4 |
EBIT 1 | - | -31.48 | -84.66 | -150.3 | -178.1 | -201.8 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | - | -29.8 | -71.9 | -143.7 | -163.7 | -192 |
Net income 1 | -19.41 | -29.8 | -71.9 | -142 | -173.2 | -192 |
Net margin | - | - | - | - | - | - |
EPS 2 | -0.3600 | -5.770 | -1.990 | -2.996 | -3.205 | -3.387 |
Free Cash Flow | - | -29.22 | - | - | - | - |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share 2 | - | - | - | - | - | - |
Announcement Date | 18/01/23 | 15/03/23 | 21/03/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - |
EBITDA 1 | - | -14.94 | -15.74 | -26.27 | -27.71 | -35.36 | -37.14 | -38.45 | -40.53 |
EBIT 1 | -10.01 | -14.94 | -15.74 | -26.27 | -27.71 | -35.36 | -36.07 | -39.18 | -39.84 |
Operating Margin | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -9.073 | -12.61 | -12.14 | -22.76 | -24.39 | -31.51 | -34.85 | -39.78 | -41.52 |
Net income 1 | -9.073 | -12.61 | -12.14 | -22.76 | -24.39 | -31.51 | -34.75 | -38.26 | -39.58 |
Net margin | - | - | - | - | - | - | - | - | - |
EPS 2 | -1.740 | -0.5100 | -0.3100 | -0.5700 | -0.6100 | -0.7000 | -0.7140 | -0.7660 | -0.7720 |
Dividend per Share | - | - | - | - | - | - | - | - | - |
Announcement Date | 15/03/23 | 15/05/23 | 07/08/23 | 07/11/23 | 21/03/24 | 09/05/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | - | - |
Net Cash position 1 | - | - | - | 105 | 137 | 137 |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow | - | -29.2 | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | -76.1% | -58.2% | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - |
Book Value Per Share | - | -8.140 | - | - | - | - |
Cash Flow per Share 2 | - | -5.660 | -2.240 | -2.670 | -3.220 | - |
Capex | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 18/01/23 | 15/03/23 | 21/03/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+41.86% | 606M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- MLYS Stock
- Financials Mineralys Therapeutics, Inc.